Phathom Pharmaceuticals Income Statement (2022-2025) | PHAT

Income Statement Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue -2.76M-5.67M-9.28M-9.60M-9.22M-9.62M-10.11M0.68M1.91M7.32M16.35M29.66M28.52M39.50M49.50M
Cost of Revenue 0.17M0.43M1.38M2.36M3.81M3.72M5.04M6.19M
Gross Profit 0.52M1.49M5.95M14.00M25.85M24.80M34.47M43.31M
Operating items
Research & Development 17.66M18.82M19.02M15.95M11.48M12.76M12.26M13.39M9.43M7.38M8.69M8.58M9.18M9.08M7.03M
Selling, General & Administrative 20.25M26.55M23.51M30.70M18.60M18.94M23.40M57.00M62.01M75.87M76.10M76.68M94.47M85.31M51.56M
Operating Expenses 37.91M45.36M42.53M46.64M30.08M31.70M35.66M70.39M71.44M83.25M84.79M85.27M103.66M94.39M58.59M
Operating Income -37.91M-45.36M-42.53M-46.64M-30.08M-31.70M-35.66M-69.88M-69.95M-77.30M-70.80M-59.42M-78.86M-59.92M-15.27M
EBIT -37.91M-45.36M-42.53M-46.64M-30.08M-31.70M-35.66M-69.88M-69.95M-77.30M-70.80M-59.42M-78.86M-59.92M-15.27M
Non-operating items
Interest & Investment Income 0.01M0.11M0.73M1.29M1.46M0.35M2.72M3.35M4.31M3.62M3.71M3.51M2.64M1.79M1.41M
Other Non Operating Income -0.01M-0.00M-0.01M-0.09M0.02M0.00M-0.20M-0.01M-0.04M-0.01M-0.01M0.05M-0.02M-0.15M-0.01M
Non Operating Income -2.76M-5.56M-8.56M-8.40M-7.74M-9.26M-7.58M-9.70M-12.90M-14.15M-14.78M-15.03M-15.45M-15.89M-14.70M
Net income details
EBT -40.66M-50.92M-51.08M-54.96M-37.83M-40.97M-43.05M-79.56M-82.81M-91.44M-85.57M-74.50M-94.29M-75.66M-29.97M
Profit After Tax -40.66M-50.92M-51.09M-55.05M-37.81M-40.97M-43.24M-79.57M-82.85M-91.45M-85.58M-74.45M-94.32M-75.81M-29.97M
Income from Continuing Operations -40.66M-50.92M-51.08M-54.96M-37.83M-40.97M-43.05M-79.56M-82.81M-91.44M-85.57M-74.50M-94.29M-75.66M-29.97M
Consolidated Net Income -40.66M-50.92M-51.08M-54.96M-37.83M-40.97M-43.05M-79.56M-82.81M-91.44M-85.57M-74.50M-94.29M-75.66M-29.97M
Income towards Parent Company -40.66M-50.92M-51.08M-54.96M-37.83M-40.97M-43.05M-79.56M-82.81M-91.44M-85.57M-74.50M-94.29M-75.66M-29.97M
Net Income towards Common Stockholders -40.66M-50.92M-51.08M-54.96M-37.83M-40.97M-43.05M-79.56M-82.81M-91.44M-85.57M-74.50M-94.29M-75.66M-29.97M
Additional items
EPS (Basic) -1.07-1.33-1.32-1.33-0.89-0.84-0.76-1.45-1.42-1.56-1.32-1.00-1.31-1.05-0.41
EPS (Weighted Average and Diluted) -1.07-1.33-1.32-1.33-0.89-0.84-0.76-1.45-1.42-1.56-1.32-1.00-1.31-1.05-0.41
Shares Outstanding (Weighted Average) 31.71M39.07M39.18M41.62M41.97M43.61M56.80M57.25M58.48M58.54M59.59M68.38M69.64M69.81M70.94M
Shares Outstanding (Diluted Average) 38.04M38.27M38.82M39.12M42.35M48.50M56.78M51.29M58.37M58.56M64.63M63.18M71.97M72.47M73.40M
EBITDA -37.91M-45.36M-42.53M-46.64M-30.08M-31.70M-35.66M-69.88M-69.95M-77.30M-70.80M-59.42M-78.86M-59.92M-15.27M
Interest Expenses 2.76M5.67M9.28M9.60M9.22M9.62M10.11M13.03M17.17M17.76M18.48M18.59M18.07M17.52M16.11M